Vir Biotechnology, Inc. · NASDAQ:VIR

Vir Biotechnology — Q3 2026 Earnings Presentation

61 slides from Vir Biotechnology's earnings presentation, Nov 4, 2026

  1. Slide 1: Corporate Overview Presentation

    Corporate Overview Presentation November 2026 2026 Vir Biotechnology, Inc. 1

  2. Slide 2: Legal disclaimer

    Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CH

  3. Slide 3: Powering the immune system to transform lives

    POWERING THE IMMUNE SYSTEM TO TRANSFORM LIVES 2026 Vir Biotechnology, Inc. 3

  4. Slide 4: Vir Bio is entering a transformative period of potential value creation

    Vir Bio is entering a transformative period of potential value creation 01 02 03 04 Execution focused Phase 3 hepatitis Clinical validation in Growing validation of leadership delta readout oncology PRO-XTEN® Strengthened leadership team Topline data External validation from Clinical proof of concep

  5. Slide 5: Landmark strategic collaboration with Astellas for VIR-5500 in prostate cancer

    Landmark strategic collaboration with Astellas maximizes potential of VIR-5500 (ASP6958) in prostate cancer i Collaboration pairs Astellas’ world class capabilities in prostate cancer with Vir Bio’s potential best-in-class T-cell engager VIR-5500, powered by PRO-XTEN® masking technology 50/50 40/60

  6. Slide 6: Gilead collaboration pairs complementary capabilities with meaningful economics

    Gilead collaboration pairs complementary capabilities with meaningful near and long-term economics Discovery + PRO-XTEN® Development + Scale Collaboration combines Vir Bio’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s o

  7. Slide 7: Delivering a differentiated pipeline in oncology and infectious disease

    Delivering a differentiated pipeline in oncology and infectious disease Driving near-term and long-term value creation siRNA Antibody Masked TCE Disease Area Product Candidate Pre-clinical Phase 1 Phase 2 Phase 3 Approval CLINICAL PROGRAMS Chronic elebsiran and tobevibart Hepatitis Delta Prostate Ca

  8. Slide 8: Upcoming milestones

    Upcoming milestones DRUG CANDIDATES PROGRAM REGIMEN CATALYST TIMING SOLSTICE: Full Week 96 data May’26 ECLIPSE 1: topline data 4Q’26 Hepatitis Delta elebsiran (siRNA) and tobevibart (mAb) ECLIPSE 2: topline data 1Q’27 ECLIPSE 3: topline data 1Q’27 PSMA-Expressing VIR-5500 (ASP6958) Phase 1 dose esca

  9. Slide 9: Our clinical programs address large and growing unmet needs

    Our clinical programs address large and growing unmet needs Infectious Disease Oncology – Solid Tumors 2032 prevalence estimate for U.S., EU4 and UK PSMA HER2 EGFR CHD VIR-5500 VIR-5818 VIR-5525 Phase 1 Elebsiran and Tobevibart Phase 1 Phase 1 Drug-treated Patients3 Phase 3 Drug-treated Patients3 Dr

  10. Slide 10: Our path to delivering transformational therapies

    Our path to delivering transformational therapies to people living with devastating diseases Commercializing our Accelerating our masked Aiming Vir Bio's discovery chronic hepatitis delta T-cell engager (TCE) engine at developing a robust (CHD) combination therapy immunotherapy portfolio pipeline of

  11. Slide 11: Our path: chronic hepatitis delta (CHD)

    Our path to delivering transformational therapies to people living with devastating diseases: chronic hepatitis delta (CHD) Commercializing our Accelerating our masked Aiming Vir Bio's discovery chronic hepatitis delta T-cell engager (TCE) engine at developing a robust (CHD) combination therapy immu

  12. Slide 12: CHD: devastating liver disease, significantly underserved with high mortality

    CHD: devastating liver disease, significantly underserved with CHD high mortality >50% 5 years 3X ~61K ~113K ~7M Liver-related Average Risk of liver Active Active viremic Active death in 10 progression cancer (HCC) viremic patients5 in viremic years1 to cirrhosis vs. HBV3 patients4 total EU (27 pati

  13. Slide 13: Accelerating access to our CHD regimen in Europe and ANZ through Norgine

    Accelerating access to our CHD regimen to patients in Europe and CHD ANZ through collaboration with Norgine • Norgine is a leading European-focused specialty pharma with market-leading products in hepatology/GI, rare disease and pediatric oncology • Exclusive commercial license in Europe, Australia,

  14. Slide 14: Complementary mechanisms designed to maximize disruption of HDV

    Complementary mechanisms designed to maximize disruption of HDV CHD Tobevibart Elebsiran (mAb) (siRNA) Inhibiting viral entry Degrading HBV RNA & reducing HBsAg production Neutralizing HDV & HBV virions cccDNA: covalently closed circular DNA; CHD: chronic hepatitis delta; HBsAg: hepatitis B virus su

  15. Slide 15: Our dual-acting regimen aims to set a new bar for best-in-class therapy

    Our dual-acting regimen aims to set a new bar for best-in-class therapy Characteristics of a best-in-class Potential of combination elebsiran and tobevibart CHD therapy Building on SOLSTICE data that achieved robust and sustained undetectable HDV Viral elimination RNA with the Phase 3 ECLIPSE progra

  16. Slide 16: Ph2 SOLSTICE trial design

    Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD CHD Study design: elebsiran and tobevibart combination therapy Q4W and tobevibart monotherapy Q2W Inclusion criteria: • HDV RNA ≥500 IU/mL combination Q4W elebsiran 200 mg and tobevibart 300 mg SC Q4W • ALT >ULN; ALT <5 × de novo

  17. Slide 17: SOLSTICE baseline characteristics

    Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD CHD Patient demographic and baseline characteristics were generally balanced across the treatment groups and all participants remained on concomitant NA therapy throughout the duration of the study Elebsiran and tobevibart Tobevib

  18. Slide 18: Monthly combo therapy achieved undetectable HDV RNA

    CHD Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD Monthly combo therapy achieved undetectable HDV RNA in 88% (28/32) of participants at Week 96 (missing = failure analysis) and 97% (31/32) of participants at Week 96 (LOCF analysis) HDV RNA TND siRNA 100 and achieving HDV RNA

  19. Slide 19: ALT normalization

    CHD Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD ALT normalization was robust and similar between elebsiran and tobevibart and tobevibart monotherapy ALT Normalization achieving ALT normalization 100 76% 80 % of participants 69% 61% 63% 60 56% 53% 53% 40 47% 20 0 0 24 48 72

  20. Slide 20: HBsAg suppression

    Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD CHD ~90% of participants receiving elebsiran and tobevibart achieved very low HBsAg values by Week 24 and maintain suppression Proportion with HBsAg <10 IU/mL 100 91% 94% mAb + 88% 88% siRNA with HBsAg <10 IU/mL 80 HBsAg % of part

  21. Slide 21: Combination therapy generally well-tolerated

    CHD Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD Combination therapy generally well-tolerated; majority of adverse events through Week 96 were grade 1 or 2 and transient Elebsiran and tobevibart Tobevibart Q2W Q4W de novo Safety or tolerability measure, n (%)a N = 33 N = 32

  22. Slide 22: SOLSTICE results show remarkable viral elimination

    CHD Ph2 SOLSTICE results to-date show remarkable viral elimination, with monthly elebsiran and tobevibart administration 88% (28/32) of elebsiran and tobevibart participants achieved undetectable HDV RNA (HDV RNA TND) ~90% of elebsiran and tobevibart participants achieved HBsAg <10 IU/mL by Week 24

  23. Slide 23: ECLIPSE Phase 3 program topline data anticipated

    CHD Initial topline data for ECLIPSE 1 anticipated in Q4 2026 FDA breakthrough ECLIPSE 1 ECLIPSE 2 ECLIPSE 3 designation Phase 3 Phase 3 Phase 2b FDA Fast Track • HDV RNA TND + ALT • HDV RNA TND at • HDV RNA TND at designation normalization at Week 24 Week 48 Week 48 • Elebsiran and • Elebsiran and

  24. Slide 24: Our path: cancer immunotherapy

    Our path to delivering transformational therapies to people living with devastating diseases: cancer immunotherapy Commercializing our Accelerating our masked Aiming Vir Bio's discovery chronic hepatitis delta T-cell engager (TCE) engine at developing a robust (CHD) combination therapy immunotherapy

  25. Slide 25: T-cell engagers are a powerful modality in cancer therapy

    T-cell engagers (TCEs) are a powerful modality in cancer therapy TCE Our masked TCEs act like Trojan Horses, powered by the PRO-XTEN® platform Non-masked TCEs hold The PRO-XTEN® masking platform tremendous potential, limited by toxicity Clinically validated, used on a blockbuster drug for hemophilia

  26. Slide 26: Our pipeline of TCEs is enabled by the PRO-XTEN masking platform

    Our unique pipeline of TCEs is enabled by the PRO-XTEN® masking TCE platform Allows our TCEs to overcome challenges of unmasked and single-masked TCEs Shields the TCE, expanding potential in cancer therapy Tumor-binding domain Variable region binds tumor-associated antigen T-cell-binding domain Vari

  27. Slide 27: Phase 1 Clinical Data: VIR-5500/ASP6958 (PSMA)

    Phase 1 Clinical Data: VIR-5500/ASP6958 (PSMA) Presented February 2026 2026 Vir Biotechnology, Inc. 27

  28. Slide 28: VIR-5500 monotherapy study in prostate cancer

    VIR-5500 monotherapy study of PSMA-targeted PRO-XTEN® VIR-5500 (PSMA) dual-masked TCE in prostate cancer All dose escalation cohorts have cleared DLT (N=58) QW dose escalation (N=26) Q3W dose escalation (N=32) Eligibility criteria: • Documented progressive 1000  2000  3000 µg/kg (N=4) 1000  2000

  29. Slide 29: Late-line mCRPC population including liver metastases

    Late-line mCRPC population including patients VIR-5500 (PSMA) with liver metastases VIR-5500 baseline characteristics VIR-5500 Study & enrollment details: NCT05997615 N=58 Heavily pre-treated participants: Median age, years (range) 68 (49-81) • Median 4 prior lines of therapy Prior lines of therapy

  30. Slide 30: VIR-5500 favorable safety profile with anti-tumor activity

    VIR-5500 Phase 1 study shows favorable safety profile with VIR-5500 (PSMA) meaningful anti-tumor activity ≥3,000 µg/kg Q3W Well tolerated with no dose limiting toxicities CRS • 12% Grade ≥ 3 TRAEs All Grades 59% (13/22) • Limited CRS 50% (29/58) primarily seen in first cycle and mostly Grade 1 (Feve

  31. Slide 31: Case Study 1: complete resolution of liver lesions

    Case Study 1: complete resolution of multiple (>14) liver lesions at VIR-5500 (PSMA) Week 9; PSA99 Q3W Cohort 800/1500/3000 µg/kg Baseline Week 9 PSA 99 ng/mL PSA 0.4 ng/mL 99% PSA Case study detail Decline • 63-year-old male • High disease burden: liver and bone lesions • 5 Prior Lines of Treatment

  32. Slide 32: Case Study 2: significant RECIST response in large liver lesions

    Case Study 2: significant RECIST response in large liver lesions VIR-5500 (PSMA) Q3W cohort 800/2000/3500 µg/kg Baseline Week 9 PSA 403 ng/mL PSA 44 ng/mL 94% Best PSA Decline Case study detail • 75-year-old male • High disease burden; liver and lymph- nodes (no bone lesions) 2 Liver Lesions SLD • 6

  33. Slide 33: Case Study 3: durable RECIST, PSMA-PET and PSA response

    Case Study 3: durable RECIST, PSMA-PET and deep PSA response VIR-5500 (PSMA) up to 8 months Q3W cohort 800/2000/3500 µg/kg Baseline Week Baseline Week 9 9 Week Week 18 18 CT/MRI CT/MRI Case study detail • 70-year-old male with peritoneal and abdominal wall lesions Baseline Week 9 Week 27 • 3 Prior l

  34. Slide 34: Case Study 4: complete response with prior radioligand therapy

    Case Study 4: complete response in diffuse lesions with prior radioligand therapy Lymph Node Biopsy Q3W Cohort 1000/2000/4000 µg/kg with Prophylactic Steroids PSMA/CD3 Duplex IHC Baseline Week 5 Baseline Week 9 PSA 81 ng/mL PSA 0.05 ng/mL PSMA membrane H-score 1401 PSMA H-score 0 100% tumor PSMA+ No

  35. Slide 35: Case Study 5: complete response with ~12 months durability

    Case Study 5: complete response with ~12 months of durability VIR-5500 (PSMA) Q3W cohort 300/600/1000 µg/kg Baseline Week 9 C1D1 C3D1 C5D1 C7D1 C9D1 C11D1 C13D1 C15D1 C17D1 PSA 42 ng/mL PSA 0.6 ng/mL 60 Local PSA (ng/mL) 40 9 Week 18 Week 27 Week 39 Week Baseline Scans Scans Scans Scans 20 Scans SD

  36. Slide 36: Well-tolerated with favorable safety profile

    Well-tolerated with favorable safety profile 12% grade ≥ 3 TRAEs, limited CRS, mostly grade 1 (Fever Only), and no DLTs Limited High-Grade Events and Tx Discontinuations Low Grade CRS in Doses ≥3,000 µg/kg Q3W (N=22) TEAEs in any Participant n (%) (N=58) 9 Grade 1 Any TEAE 58 (100) 8 Participants wi

  37. Slide 37: Dose response relationship: deeper PSA declines at higher doses

    Dose response relationship: VIR-5500 (PSMA) deeper PSA declines and confirmed PSA responses at higher doses 100 30 μg/kg QW 300/600/1000 μg/kg Q3W 60 μg/kg QW 500/1000/2000 μg/kg Q3W 120/180/180 μg/kg QW 800/1500/3000 μg/kg Q3W PSA Best % Change from Baseline (PCWG3)# 200/300/400 μg/kg QW 1000/2000/

  38. Slide 38: Deep PSA declines observed as early as Cycle 1 Day 8

    Deep PSA declines observed as early as Cycle 1 Day 8, VIR-5500 (PSMA) evidence of concordant RECIST responses in evaluable patients Doses ≥ 3000 ug/kg Q3W 100 ≥ 3000 µg/kg Q3W 800/1500/3000 μg/kg Q3W 1000/2000/3000 μg/kg Q3W Any PSA Decline 15/17 (88%) PSA Best % Change from Baseline (PCWG3)^ 75 800

  39. Slide 39: Reduction in PSMA total tumor volume by PSMA PET

    Reduction in PSMA total tumor volume by central PSMA PET analysis, RECIP responses associated with deep PSA declines and RECIST responses Doses ≥ 3000 ug/kg Q3W RECIP 1.0 Classification 100 800/1500/3000 μg/kg Q3W Complete Response % Change in PSMA Total Tumor Volume 800/2000/3500 μg/kg Q3W Partial

  40. Slide 40: Robust RECIST responses with VIR-5500 monotherapy

    Robust RECIST responses with VIR-5500 monotherapy in VIR-5500 (PSMA) RECIST-evaluable participants Doses ≥ 3000 ug/kg Q3W 100 800/1500/3000 μg/kg Q3W 1000/2000/3000 μg/kg Q3W 80 71.43 800/2000/3500 μg/kg Q3W 1000/2000/4000 μg/kg Q3W (+C1 Steroid Prophylaxis) 60 Best Change from Baseline ORR 45% (5/1

  41. Slide 41: RECIST responses concordant with deep PSA responses

    RECIST responses concordant with deep PSA responses VIR-5500 (PSMA) Doses ≥ 3000 ug/kg Q3W Initial Stable Disease followed by disease progression due to 80 Progressive Disease with PSMA-negative lesions in the metastases to the liver and new bone metastases resulting in spinal fracture liver; only r

  42. Slide 42: Emerging evidence of PSA and radiographic durability

    Emerging evidence of PSA and radiographic durability VIR-5500 (PSMA) Doses ≥ 3000 ug/kg Q3W, CRS Restricted to Early Cycles 0 2 4 6 8 10 Months 800 / 1500 / 3000 µg/kg * ^ 1000 / 2000 / 3000 µg/kg Time on Treatment Ongoing 800 / 2000 / 3500 µg/kg PSA50 PSA90 uPR cPR cCR G1 CRS 1000 / 2000 / 4000 µg/

  43. Slide 43: VIR-5500: clinical proof of concept and advancement into earlier settings

    VIR-5500: Clinical proof of concept established with rapid advancement into earlier prostate cancer settings MONOTHERAPY COMBINATION THERAPY NEXT STEPS VIR-5500 (ASP6958) Taxane-naïve mCRPC VIR-5500 + enzalutamide Earlier-line mCRPC opportunity Taxane-naïve mCRPC DOSE EXPANSION RLT-naïve mCRPC VIR-5

  44. Slide 44: Our clinical pipeline of masked TCEs demonstrates promise of PRO-XTEN

    Our clinical pipeline of masked TCEs demonstrates the promise of the PRO-XTEN® platform VIR-5500/ ASP6958 VIR-5818 VIR-5525 PSMA | PROSTATE CANCER HER2 | MULTIPLE SOLID TUMORS EGFR | MULTIPLE SOLID TUMORS Clinical proof of concept established Currently in dose escalation Currently in dose escalation

  45. Slide 45: Financials and Closing

    Financials and Closing 2026 Vir Biotechnology, Inc. 45

  46. Slide 46: Q3 2026 Financial Results

    Q3 2026 Financial Results Three Months Ended September 30, Change $ in millions, except for headcount numbers and % 2026 2025 $ % Total revenues $ (0.2) $ 0.2 $ (0.4) (200)% Operating expenses: Research and development(1) 80.0 151.5 (71.5) (47)% Selling, general and administrative(1) 24.4 22.2 2.2 1

  47. Slide 47: Multiple value-creating catalysts ahead, supported by a strong balance sheet

    Multiple value-creating catalysts ahead, supported by a strong balance sheet Chronic hepatitis delta Universal masked TCEs Discovery engine VIR-5500 pivotal trials to initiate in ECLIPSE 1 topline data in 4Q 2026 2027 Multiple candidates progressing to ECLIPSE 2 & 3 topline data in 1Q 2027 VIR-5818

  48. Slide 48: Patients are waiting

    PATIENTS ARE WAITING 2026 Vir Biotechnology, Inc. 2026 Vir Biotechnology, Inc. 48

  49. Slide 49: Phase 1 Clinical Data: VIR-5818 (HER2)

    Phase 1 Clinical Data: VIR-5818 (HER2) Presented January 2025 2026 Vir Biotechnology, Inc. 49

  50. Slide 50: The first clinical stage masked HER2 TCE in ongoing Phase 1

    The first clinical stage masked HER2 TCE in ongoing Phase 1 VIR-5818 (HER2) Part 1: Monotherapy Dose - Completed Part 2: Pembrolizumab Combination Recommended expansion Eligibility: + dose and schedule Pembrolizumab HER2 IHC2-3+, ISH+, or VIR-5818 100  300  1000 µg/kg mutant Q3W QW and Q3W Exhaust

  51. Slide 51: Minimal unmasked TCE in circulation and potential for Q3W dosing

    Minimal unmasked TCE in circulation and potential for Q3W dosing VIR-5818 (HER2) Minimal unmasked TCE outside the tumor Half-life of ~ 6 days unlocks potential Q3W dosing VIR-5818 and uTCE PK, First Cycle* VIR-5818 PK, First Dose 1000 Plasma Concentration, nM 100 10 1 0.1 0.01 0 7 14 21 Nominal Time

  52. Slide 52: VIR-5818 is not dose-limited by CRS

    Preliminary safety data indicates VIR-5818 is not dose-limited by CRS VIR-5818 (HER2) Highly Tolerable Safety Low Cytokine Levels, Even at Higher Doses TRAE (max grade) in >15% of pts Peaks of IL-6 Secretion Post VIR-5818 Dosing VIR-5818 Grade 1 Grade 2 Grade ≥ 3 N = 79 N (%) N (%) N (%) Peak IL-6 I

  53. Slide 53: Notable tumor shrinkage observed during dose escalation

    Notable tumor shrinkage observed during dose escalation VIR-5818 (HER2) HER2+ Solid Tumors (Doses ≥ 400 µg/kg) Efficacy detail: • ≥ 400 µg/kg drive significant RECIST responses Breast cancer patient case study o Dose escalation continues in QW and Q3W regimens • 50% observed tumor shrinkage (10/20 p

  54. Slide 54: A patient's journey: dramatic response in advanced HER2+ breast cancer

    A patient’s journey: dramatic response in advanced HER2+ breast VIR-5818 (HER2) cancer Tumor pain, inflammation Day 1 Baseline Cycle 1 Day 8 Cycle 2 Day 1 VIR-5818 Case Study Compelling activity in breast cancer patient by Cycle 1 with transformative clearance of tumor 9 prior lines of therapy, Cycl

  55. Slide 55: Deep responses at early doses in MSS colorectal cancer

    Deep responses at early doses in MSS colorectal cancer, a tumor VIR-5818 (HER2) type traditionally resistant to immunotherapy HER2+ Colorectal Cancer (All Patients Shown are MSS) Dose Levels Early Phase 1 efficacy 100-300 µg/kg 400 µg/kg Activity HER2+ CRC ≥400 µg/kg 600 µg/kg 800 µg/kg cPR 2/6 (33%

  56. Slide 56: Patient Case Study: years on treatment, exceptional durability

    Patient Case Study: 2 years on treatment, exceptional durability VIR-5818 (HER2) Rapid and Sustained Decrease Over Time Dose-Dependent Tumor Shrinkage 900 CEA 899 ng/mL Dose Levels Change in Target Tumors Size from Baseline 0 Change in SLD from Baseline (%) 800 60 µg/kg Dose Levels 120 µg/kg 700 -10

  57. Slide 57: Molecular evidence of anti-tumor activity across cancer types

    Molecular evidence of anti-tumor activity across multiple cancer VIR-5818 (HER2) types Molecular Responses: ctDNA (Step-up doses only) Detail: 100 • High value of biomarkers for Percent Change from Baseline (%) immunologics 50 • RECIST responses may be confounded by tumor 0 inflammation • With on-tr

  58. Slide 58: A potential first-in-class HER2 TCE to validate PRO-XTEN

    A potential first-in-class HER2 TCE designed to clinically validate the VIR-5818 (HER2) PRO-XTEN® platform Clear activity based on early Phase 1 data with potential for long-term durable responses Emerging activity: wide TI in heavily pretreated population • Unprecedented tolerability: no Gr3+ CRS,

  59. Slide 59: Phase 1 Clinical Program: VIR-5525 (EGFR)

    Phase 1 Clinical Program: VIR-5525 (EGFR) 2026 Vir Biotechnology, Inc. 59

  60. Slide 60: VIR-5525 Phase 1 study design

    VIR-5525 Phase 1 study design: dose escalation and expansion VIR-5525 (EGFR) Part 3 & 4: Pembrolizumab Combination Part 1 & 2: Monotherapy Dose Escalation & Expansion Dose Escalation & Expansion Indications: + Highest Potential Dose NSCLC (nonsquamous or squamous histology), CRC, Continued Dose Esca

  61. Slide 61: Preclinical data show potent activity and safety margin with PRO-XTEN masking

    Preclinical data demonstrate potent activity and substantial safety VIR-5525 (EGFR) margin with PRO-XTEN® masking Outside Tumor: masking is maintained, leading to In Tumor: similar anti-tumor activity in ~10,000-fold shift in cytotoxicity PRO-XTEN® masked vs. unmasked EGFR TCE Anti-tumor activity in

Vir Biotechnology — Q3 2026 Earnings Presentation on 6ix